

Resource Summary Report

Generated by [RRID](#) on Aug 7, 2026

xCT/SLC7A11 Antibody

RRID:AB_2800296

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 98051, RRID:AB_2800296

Antibody Information

URL: http://antibodyregistry.org/AB_2800296

Proper Citation: Cell Signaling Technology Cat# 98051, RRID:AB_2800296

Target Antigen: SLC7A11

Host Organism: rabbit

Clonality: unknown

Comments: Applications: W

Antibody Name: xCT/SLC7A11 Antibody

Description: This unknown targets SLC7A11

Target Organism: m

Antibody ID: AB_2800296

Vendor: Cell Signaling Technology

Catalog Number: 98051

Record Creation Time: 20250820T022731+0000

Record Last Update: 20250820T133833+0000

Ratings and Alerts

No rating or validation information has been found for xCT/SLC7A11 Antibody.

No alerts have been found for xCT/SLC7A11 Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Aussel A, et al. (2026) Tumor metabolic adaptation induced by L-asparaginase reveals a vulnerability to PARP1/2 inhibitor in B-cell lymphomas. Nature communications, 17(1).

Silva PHF, et al. (2026) Chemotherapy-Induced Oral Mucosal Injury Is Defined by p53 Activation, Cell Cycle Arrest and Diverse Epithelial Progenitor Dynamics. bioRxiv : the preprint server for biology.

Sabatier M, et al. (2026) GPX4 Inhibitor Resistance and Metastatic Features in Triple-Negative Breast Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(23), e23198.

Xiao B, et al. (2025) Treadmill exercise in combination with acousto-optic and olfactory stimulation improves cognitive function in APP/PS1 mice through the brain-derived neurotrophic factor- and Cygb-associated signaling pathways. Neural regeneration research, 20(9), 2706.

Graziani V, et al. (2025) SLC7A11 protects amoeboid-disseminating cancer cells from oxidative stress. Cell reports, 44(7), 115939.

Wang Z, et al. (2025) NANS suppresses NF- κ B signaling to promote ferroptosis by perturbing iron homeostasis. Cell reports, 44(5), 115701.

Yamauchi T, et al. (2024) Epigenetic repression of de novo cysteine synthetases induces intra-cellular accumulation of cysteine in hepatocarcinoma by up-regulating the cystine uptake transporter xCT. Cancer & metabolism, 12(1), 23.

Zhang X, et al. (2024) CRISPR screening identifies PRMT1 as a key pro-ferroptotic gene via a two-layer regulatory mechanism. Cell reports, 43(9), 114662.

Lin H, et al. (2024) Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance. Cancer cell, 42(12), 2032.

Xu J, et al. (2023) Constitutively active autophagy in macrophages dampens inflammation through metabolic and post-transcriptional regulation of cytokine production. Cell reports, 42(7), 112708.

Liu T, et al. (2023) Rapamycin reverses ferroptosis by increasing autophagy in MPTP/MPP⁺-induced models of Parkinson's disease. Neural regeneration research, 18(11), 2514.

Yoon SJ, et al. (2023) Comprehensive Metabolic Tracing Reveals the Origin and Catabolism of Cysteine in Mammalian Tissues and Tumors. *Cancer research*, 83(9), 1426.

Liao P, et al. (2022) CD8+ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. *Cancer cell*, 40(4), 365.

Yao F, et al. (2021) A targetable LIFR-NF- κ B-LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis. *Nature communications*, 12(1), 7333.